Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myelomaJoaquín Martínez‐López, Bruno Paiva, Noemí Puig et al.|Leukemia|2017Cited by 51
CNL and aCML should be considered as a single entity based on molecular profiles and outcomesGonzalo Carreño‐Tarragona, Nicholas C.P. Cross, Alberto Álvarez‐Larrán et al.|Blood Advances|2023Cited by 32
Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencingYanira Ruiz‐Heredia, Joaquín Martínez‐López, Beatriz Sánchez-Vega et al.|Haematologica|2018Cited by 15
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical TrialJuan Manuel Rosa-Rosa, Joaquín Martínez‐López, Isabel Cuenca et al.|Cancers|2022Cited by 15
Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma PatientsBeatriz Sánchez-Vega, Joaquín Martínez‐López, Rafael Alonso et al.|Blood|2016Cited by 4